Form 8-K

8-K — PDS Biotechnology Corp

Accession: 0001140361-26-016684

Filed: 2026-04-24

Period: 2026-04-24

CIK: 0001472091

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — ef20071434_8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (ef20071434_ex99-1.htm)

GRAPHIC (ef20071434_ex99-1slide1.jpg)

GRAPHIC (ef20071434_ex99-1slide2.jpg)

GRAPHIC (ef20071434_ex99-1slide3.jpg)

GRAPHIC (ef20071434_ex99-1slide4.jpg)

GRAPHIC (ef20071434_ex99-1slide5.jpg)

GRAPHIC (ef20071434_ex99-1slide6.jpg)

GRAPHIC (ef20071434_ex99-1slide7.jpg)

GRAPHIC (ef20071434_ex99-1slide8.jpg)

GRAPHIC (ef20071434_ex99-1slide9.jpg)

GRAPHIC (ef20071434_ex99-1slide10.jpg)

GRAPHIC (ef20071434_ex99-1slide11.jpg)

GRAPHIC (ef20071434_ex99-1slide12.jpg)

GRAPHIC (ef20071434_ex99-1slide13.jpg)

GRAPHIC (ef20071434_ex99-1slide14.jpg)

GRAPHIC (ef20071434_ex99-1slide15.jpg)

GRAPHIC (ef20071434_ex99-1slide16.jpg)

GRAPHIC (ef20071434_ex99-1slide17.jpg)

GRAPHIC (ef20071434_ex99-1slide18.jpg)

GRAPHIC (ef20071434_ex99-1slide19.jpg)

GRAPHIC (ef20071434_ex99-1slide20.jpg)

GRAPHIC (ef20071434_ex99-1slide21.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: ef20071434_8k.htm · Sequence: 1

false0001472091NASDAQ00014720912026-04-242026-04-24

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 24, 2026

PDS BIOTECHNOLOGY CORPORATION

(Exact Name of Registrant as Specified in Charter)

Delaware

001-37568

26-4231384

(State or Other Jurisdiction of Incorporation)

(Commission File Number)

(I.R.S. Employer Identification No.)

303A College Road East,

Princeton, NJ 08540

(Address of Principal Executive Offices, and Zip Code)

(800) 208-3343

Registrant’s Telephone Number, Including Area Code

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the

following provisions (see General Instruction A.2. below):

☐

Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which

registered

Common Stock, par value $0.00033 per share

PDSB

The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this

chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new

or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Yes ☐ No ☐

Item 8.01

Other Events.

On April 24, 2026, the Company updated its corporate presentation deck.

A copy of the corporate presentation deck is filed herewith as Exhibit 99.1 and incorporated by reference herein.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

Exhibit

Number

Description

99.1

Corporate Presentation (April 2026).

104

Cover Page Interactive Data File (embedded within the Inline XBRL Document).

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its

behalf by the undersigned hereunto duly authorized.

PDS BIOTECHNOLOGY CORPORATION

Date: April 24, 2026

By:

/s/ Frank Bedu-Addo, Ph.D.

Name: Frank Bedu-Addo, Ph.D.

Title: President and Chief Executive Officer

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: ef20071434_ex99-1.htm · Sequence: 2

Exhibit 99.1

Precision Designed Science for Cancer Patients NASDAQ: PDSB April 2026

Forward-Looking Statements This communication contains forward-looking

statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the

“Company”) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company’s

management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions,

and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “forecast,” “guidance”, “outlook” and other similar expressions among others. Forward-looking

statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement

as a result of various factors, including, without limitation: the Company’s ability to protect its intellectual property rights; the Company’s anticipated capital requirements, including the Company’s anticipated cash runway and the

Company’s current expectations regarding its plans for future equity financings; the Company’s dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the

risks that raising such additional capital may restrict the Company’s operations or require the Company to relinquish rights to the Company’s technologies or product candidates; the Company’s limited operating history in the Company’s

current line of business, which makes it difficult to evaluate the Company’s prospects, the Company’s business plan or the likelihood of the Company’s successful implementation of such business plan; the timing for the Company or its

partners to conduct clinical trials for PDS0101 (Versamune® HPV), PDS01ADC, PDS0103 (Versamune® MUC1) and other Versamune® based product candidates; the future success of such trials; the successful implementation of the Company’s research

and development programs and collaborations, including any collaboration studies concerning PDS0101, PDS01ADC, PDS0103 and other Versamune® based product candidates and the Company’s interpretation of the results and findings of such

programs and collaborations and whether such results are sufficient to support the future success of the Company’s product candidates; the success, timing and cost of the Company’s or its partners’ ongoing clinical trials and anticipated

clinical trials for the Company’s current product candidates, including statements regarding response rates, the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund its

disclosed clinical trials, which assumes no material changes to the Company’s currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim or preliminary results

(including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of the Company’s ongoing clinical trials; any Company statements about its understanding of product candidates

mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs and any collaboration studies; the Company’s ability to continue as a going concern; and other factors, including

legislative, regulatory, political and economic developments not within the Company’s control. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and

should be read in conjunction with statements that are included herein and elsewhere, including the other risks, uncertainties, and other factors described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition

and Results of Operations” and elsewhere in the documents we file with the U.S. Securities and Exchange Commission. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law,

the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.  Versamune® is a registered

trademark of PDS Biotechnology Corporation. KEYTRUDA® is a registered trademark of Merck Sharp and Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

months 12-18 months for current standard of care1 Keytrud (pembrolizumab)

benchmark in First-line (1L) treatment for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (1L R/M HNSCC) 77.4% disease control rate with PDS0101 in 1L R/M HNSCC Phase 3 VERSATILE-003 pivotal trial FDA alignment on

Progression-Free-Survival (PFS) as interim primary endpoint provides for accelerated pathway to approval Partnerships with leading cancer institutions MD Anderson Mayo Clinic National Cancer Institute Targeting HPV16+

Cancers REGISTRATIONAL TRIAL COMPELLING CLINICAL DATA POTENTIAL ACROSS CANCERS 4 clinical trials completed 39.3 median overall survival No head-to-head studies have been performed.

HPV16 HPV18 HPV 31/33/45/52/58 HPV 35/39/51/56/59/68 HPV-negative HPV16+

Tumors Represent the Largest and Fastest Growing Type of HNSCC HPV16+ HNSCC Rapidly Increasing in the US and EU Poor uptake of HPV vaccine2,3 Changing sexual behavior4 Unique pathophysiology of HPV165 Annual Number of Oropharyngeal

Cancer Cases HPV16+ PDS Biotech focus

PUBLISHED EVIDENCE Two head-to-head studies demonstrate that HPV16-positive

patients have statistically worse survival compared to other patient groups: Early-stage HNSCC: HPV16+ patients had worse survival than other HPV+ (P16+) patients6 Advanced oral cancer: HPV16+ patients had worse survival than HPV-negative

patients7 Keytruda® (pembrolizumab) + chemotherapy median survival1 12–18 months in recurrent/metastatic setting HPV16+ Patients Have No Targeted Therapies and Worse Clinical Outcomes CURRENT STANDARD OF CARE 2 1 A targeted approach

for HPV16+ patients represents a significant opportunity

HOW IT WORKS 1 2 3 ATTACK Killer T cells hunt & destroy matching

tumors Immunologically active R-enantiomer of1,2-dioleoyl-trimethyl-ammonium (R-DOTAP) R-DOTAP forms spherical bilayers in aqueous environment The Versamune® Platform Provides Mechanism for Targeted Immune Attack Proprietary

immunotherapy platform designed to generate cytotoxic CD8+ T-cell responses against specific tumor antigens8 Lead compound PDS0101 targets HPV16 E6/E7 viral antigens, enabling targeted immune attack on HPV-driven cancers8 Nanoparticles

sized 100-200nm to promote uptake by the immune system ACTIVATE Dendritic cells absorb & present proteins to T cells UPTAKE Promotes uptake of tumor proteins by immune cells

PDS0101: Training the Immune System to Find and Destroy HPV16+

Tumors8 CD4+helper T cell CD8+killer T cell HPV16 E6 & E7 Versamune®Activated CD8+Killer T Cell ImmuneCheckpointInhibitor Versamune® +HPVmix (PDS0101) Targeted CD8+ T CellsTracks to Tumor Dendritic Cell MHC class II MHC class

I LYMPH NODE TUMOR Subcutaneous Injection of PDS0101 stimulates uptake by dendritic cells & accumulates in the lymph nodes Activated T cells attack anddestroy tumor, while immune checkpoint inhibitor restores pre-existing T cell

responses 3 T cells increase production of HPV16 specific CD8 killer & CD4 helper T cells, which recognize and infiltrate tumor 2 1

Therapy / Treatment Indication P2 P3 Partner Versamune® PDS0101 +

pembrolizumab vs. pembrolizumab (VERSATILE-003) HPV16-positive recurrent/metastatic head and neck cancer PDS0101 + ChemoRT* (IMMUNOCERV) Locally advanced cervical cancer PDS0101 +/- pembrolizumab Locally advanced head and neck

cancer Versamune®+PDS01ADC* PDS0101 + PDS01ADC + immune checkpoint inhibitor (ICI) HPV16-positive recurrent/metastatic cancers PDS01ADC PDS01ADC + hepatic artery infusion pump (HAIP) Advanced Liver-Associated Cancers Metastatic

colorectal cancer Intrahepatic cholangiocarcinoma Metastatic adrenocortical carcinoma PDS01ADC + enzalutamide vs. enzalutamide Biochemically recurrent prostate cancer PDS01ADC + docetaxel Metastatic Prostate Cancer Castration

sensitive prostate cancer Castration resistant prostate cancer FDA Fast Track (In progress) Complete Complete Complete In Progress In Progress In Progress Pipeline Expansion Across Multiple Indications *ChemoRT =

chemoradiotherapy Partnerships with Leading Cancer Research Institutions

Endpoints Single-arm study 31 sites in US and EU 2 Cohorts: ICI

Naïve ICI Resistant HPV16-positive R/M HNSCC tumors ≥18 years of age Combined positive score (CPS) ≥1 PDS0101 5 doses: 1 mL Subcutaneous injection Q3W at Cycles 1, 2, 3, 4 & 12) + Pembrolizumab 200mg IV Q3W up to 35 Cycles (2

years) Primary Best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR) per RECIST v1.1 Key Secondary Overall Survival (OS) Progression Free Survival (PFS) per RECIST v1.1 Safety and

tolerability StudyDesign Key Entry Criteria for ICI Naïve Subjects Study Treatment Lead Clinical Program Evaluating PDS0101 in Combination with Checkpoint Inhibitors VERSATILE-002: PDS0101 + Pembrolizumab in 1L HPV16+ R/M HNSCC

PDS0101 + Pembrolizumab: mOS of 39.3 Months9 mOS = Median Overall

Survival. No head-to-head studies have been performed. 12-18 Months mOS is Benchmark with Pembrolizumab and Pembrolizumab + Chemotherapy1 Durable Survival: 11 Patients Surpassed 30 Months

PDS0101: Near or Complete Tumor Shrinkage in Difficult-to-Treat

Patients9 *Investigator assessment. 63% with CPS 1-199 Confirmed disease control rate of 77.4% ORR of 35.8% 21% of patients had tumor regression of 90-100%

PDS0101: Well-tolerated with a Low Incidence of Adverse Events9 *Occurred 1

year after completing PDS0101 therapy while patient was still on pembrolizumab. Treatment related adverse events (TRAEs) by Grade in ICI naïve and resistant patients n (%) Any Combination TRAE 76 (87.4) Grade 1 40 (46.0) Grade

2 26 (29.9) Grade 3 8 (9.2) Grade 4 1 (1.1)* Grade 5 0 Most common Non-Injection Site Reaction TRAEs n (%) Fatigue 30 (34.5) Headache 13 (14.9) Diarrhea 10 (11.5)

VERSATILE-003: Pivotal Phase 3 in Progress PDS0101 + pembrolizumab in 1L

HPV16-positive R/M HNSCC Key Eligibility Criteria HPV16-positive HNSCC CPS ≥1 ≥18 years of age ECOG 0-1 Primary Endpoints Overall Survival (OS) Progression free survival (PFS) Secondary Endpoints Objective Response Rate

(ORR) Disease Control Rate (DCR) Duration of Response (DoR) Randomized controlled trial 1:1 randomization 50/50: high/low CPS N = 252 PDS0101 Dosing 5 SC Doses Cycles 1-4 & 12 Principal Investigator and Member of Steering

Committee, Dr. Katharine Price, MD, Mayo Clinic, Rochester, MN Patient Recruitment InterimAnalysis 1 (PFS) Study Start Patient Recruitment Survival Follow-up Survival Follow-up Final Analysis (mOS) InterimAnalysis

2 (PFS) PDS0101 + Pembrolizumab Pembrolizumab

Well-Positioned in 1L HPV16+ R/M HNSCC No head-to-head studies have been

performed. Combinations with pembrolizumab PDS0101: Only Subcutaneous Combination Therapy in Late-stage Development for 1L HPV16+ HNSCC Genmab10 Bicara11 BioNTech12 PDS Biotech Median OS Not disclosed 21.3 months 22.6 months 39.3

months 95% CI (23.9, NE) Population All comers HPV-negative HPV16-positive HPV16-positive Administration Convenience IV Q2W until PD or toxicity IV QW (D1, D8, D15) IV Q1W 8X then Q3W for 24mos 5 subcutaneous injections of

PDS0101 Cycles 1-4 Q3W & then Cycle 12

Tumor-targeted IL-12 immunocytokine THE SOLUTION PDS01ADC attaches IL-12 to

an antibody (NHS76) that seeks out dying tumor cells, delivering treatment directly where it's needed while minimizing systemic inflammation13,14 HOW IT WORKS Finds the TumorThe NHS76 antibody targets DNA that is exposed when tumor cells

die Activates Immune CellsPDS01ADC recruits T cells and NK cells to attack the tumor from within Minimizes Side EffectsLocalized delivery means patients avoid the systemic inflammation that free IL-12 causes THE CHALLENGE IL-12 is a

powerful NK* and T cell activator that helps fight cancer, but injecting it into the bloodstream causes serious systemic inflammation NHS76 Tumor Necrosis Targeting Antibody – Binds to exposed DNA De-immunized Junction PDS01ADC: Novel

Investigational Tumor Targeting Interleukin-12 (IL-12) Immunocytokine13,14 *NK = Natural killer Encouraging tolerability and potency demonstrated in over 330 patients IL-12 (p40 clipping-resistant) IL-12 (p40 clipping-resistant)

Enrollment completion PFS data readout (Submission of interim data to

FDA) PDS01ADC + HAIP Stage 1 Cholangiocarcinoma PDS01ADC + Enzalutamide vs Enzalutamide Biochemically Recurrent Prostate cancer PDS01ADC + Docetaxel Castration Resistant Prostate cancer Final Data ReadoutPDS01ADC + HAIP Colorectal

cancer PDS0101 + CRT Phase 2 data publication Cervical cancer VERSATILE-003 (Head and neck cancer) 2Q 2026 PDS01ADC + HAIPPreliminary data publicationColorectal cancer16 Upcoming Catalysts CRT = Chemoradiotherapy PFS = Progression

free survival PHASE 2 TRIALS 2H 2026 1H 2027 2H 2027 1Q 2026 PDS01ADC + docetaxel in metastatic castration resistant prostate cancerPreliminary data publication15 Adoption of Amended Protocol (FDA)

COVERAGE Composition and method claims protecting both platform technology

and product candidates 13 Patent Families PDS0101 EXCLUSIVITY 2041/2042 Global IP Portfolio Covers Key Commercial Markets 8 North America Asia Pacific Europe Middle

East USA Canada Mexico EU/UK Israel China Japan Australia KEYMARKETS

HPV16+ HNSCC PDS Platform is a Significant Value Creation

Opportunity Locally advanced cervical cancer Castration resistant prostate cancer HPV16+ R/M cancers Biochemically recurrent prostate cancer Metastatic colorectal & liver-associated cancers >$1.0B TOTAL ADDRESSABLE MARKET –

US ONLY HPV16+ HNSCC (PDS0101) HPV16+ gynecologic cancers (PDS0101) Prostate cancer (PDS01ADC) Metastatic colorectal (PDS01ADC) Current Focus Next Steps Commercialization Types Expansion into Pivotal Studies in Various

Indications Path to Commercialization PDS01ADC + Docetaxel IMMUNOCERV Versamune® + ICI + PDS01ADC PDS01ADC + Enzalutamide PDS01ADC + HAIP >$2.0B >$6.0B ~$2.0B 39.3 77.4 174 months % Median Overall Survival (12–18 mo.

benchmark)* Disease Control Rate Dosed in Phase 1 and Phase 2 Trials *No head-to-head studies have been performed. patients

The only investigational therapy in Phase 3 with 30+ months median survival in

1L HPV16+ R/M HNSCC $1.2 - 1.8B The PDS Opportunity World-Class Research PartnersNCI, Mayo Clinic, MD Anderson and leading cancer centers with studies externally funded, independently validated Global IP Protection13 patent families

across 8 markets; PDS0101 exclusivity through 2041/2042 Registrational TrialPhase 3 VERSATILE-003 underway; FDA-aligned on primary endpoint for accelerated approval Encouraging Data Supports Broader DevelopmentPDS01ADC programs in

colorectal and prostate cancer progressing toward potential advancement US Market Potential* *Company estimates based on external market research

Thank You NASDAQ: PDSB April 2026

References Harrington, KJ, Burtness B, Greil R, et al. Keytruda With or

Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study. J Clin Oncol. 2022;41:790-802. https://doi.org/10.1200/JCO.21.02508. Damgacioglu H, Sonawane K,

Chhatwal J, et al. Long-term impact of HPV vaccination and COVID-19 pandemic on oropharyngeal cancer incidence and burden among men in the USA: A modeling Study. The Lancet Regional Health – Americas. 2022;8:100143. Tabatabaeian H et al,

Navigating therapeutic strategies: HPV classification in head and neck cancer, British Journal of Cancer. (2024) 131: 220-230. Landy R, et al JNCI: Upper age limits for US male human papillomavirus vaccination for oropharyngeal cancer

prevention: a microsimulation-based modeling study; Journal of the National Cancer Institute, 2023, 115(4), 429–436. Luo X et al; HPV16 drives cancer immune escape via NLRX1-mediated degradation of STING; J Clin Invest.

2020;130(4):1635–1652. Ziai H. et al; Does HPV Subtype Predict Outcomes in Head and Neck Cancers?; International Journal of Otolaryngology; Volume 2021, Article ID 6672373; https://doi.org/10.1155/2021/6672373. Lee L et al; Human

Papillomavirus-16 Infection in Advanced Oral Cavity Cancer Patients Is Related to an Increased Risk of Distant Metastases and Poor Survival; PLOS One; July 2012, Volume 7, Issue 7, e40767. Gandhapudi SK, Ward M, Bush JPC, Bedu-Addo F, Conn

G, Woodward JG. Antigen Priming with Enantiospecific Cationic Lipid Nanoparticles Induces Potent Antitumor CTL Responses through Novel Induction of a Type I IFN Response. J Immunol. 2019;202:3524-3536 Weiss J et al. VERSATILE-002: Overall

Survival of HPV16 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients Treated with T Cell Stimulating Immunotherapy PDS0101 and Keytruda. Poster Presented: ASCO Congress 2025; June 2, 2025. Van Herpen CML et al,

Petosemtamab (MCLA-158) with pembrolizumab as first line (1L) treatment of PD-L1+ recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC): Phase 2 Trial, ASCO 2025 Cortese T, Ficerafusp Alfa/Pembrolizumab Receives FDA BTD

in Frontline HNSCC, Cancer Network, October 14, 2025 Saba NF et al, Exploratory analysis of antitumor activity and translational results from the safety run-in of AHEAD-MERIT, a Phase 2 trial of first-line pembrolizumab plus the

fixed-antigen cancer vaccine BNT113 in advanced HPV16+ HNSCC, ESMO 2024 Minnar CM et al (2024) Preclinical and clinical studies of a tumor targeting IL-12 immunocytokine. Front. Oncol. 13:1321318.doi: 10.3389/fonc.2023.1321318 Greiner JW

et al NHS-IL12, a Tumor-Targeting Immunocytokine; ImmunoTargets and Therapy 2021:10 155–169 Abel ML et al, Abstract PR008: Docetaxel and the Tumor Targeting Interleukin-12 (IL-12) PDS01ADC in Patients with Metastatic Castration Resistant

Prostate Cancer (mCRPC), Cancer Research, Vol. 86, Issue 2 Supplement, 15 January 2026 Eade AV et al; Tumor-Targeted IL-12 (PDS01ADC) with Hepatic Artery Infusion Pump Therapy for Colorectal Liver Metastases: Interim Analysis of a

Non-randomized Phase II Tria; JCO Oncol Adv 3, e2500173 (2026) Vol. 3 #1

GRAPHIC

Filename: ef20071434_ex99-1slide1.jpg · Sequence: 6

Binary file (105450 bytes)

Download ef20071434_ex99-1slide1.jpg

GRAPHIC

Filename: ef20071434_ex99-1slide2.jpg · Sequence: 7

Binary file (366038 bytes)

Download ef20071434_ex99-1slide2.jpg

GRAPHIC

Filename: ef20071434_ex99-1slide3.jpg · Sequence: 8

Binary file (141821 bytes)

Download ef20071434_ex99-1slide3.jpg

GRAPHIC

Filename: ef20071434_ex99-1slide4.jpg · Sequence: 9

Binary file (97021 bytes)

Download ef20071434_ex99-1slide4.jpg

GRAPHIC

Filename: ef20071434_ex99-1slide5.jpg · Sequence: 10

Binary file (133021 bytes)

Download ef20071434_ex99-1slide5.jpg

GRAPHIC

Filename: ef20071434_ex99-1slide6.jpg · Sequence: 11

Binary file (124652 bytes)

Download ef20071434_ex99-1slide6.jpg

GRAPHIC

Filename: ef20071434_ex99-1slide7.jpg · Sequence: 12

Binary file (139538 bytes)

Download ef20071434_ex99-1slide7.jpg

GRAPHIC

Filename: ef20071434_ex99-1slide8.jpg · Sequence: 13

Binary file (160816 bytes)

Download ef20071434_ex99-1slide8.jpg

GRAPHIC

Filename: ef20071434_ex99-1slide9.jpg · Sequence: 14

Binary file (155279 bytes)

Download ef20071434_ex99-1slide9.jpg

GRAPHIC

Filename: ef20071434_ex99-1slide10.jpg · Sequence: 15

Binary file (98587 bytes)

Download ef20071434_ex99-1slide10.jpg

GRAPHIC

Filename: ef20071434_ex99-1slide11.jpg · Sequence: 16

Binary file (124671 bytes)

Download ef20071434_ex99-1slide11.jpg

GRAPHIC

Filename: ef20071434_ex99-1slide12.jpg · Sequence: 17

Binary file (106124 bytes)

Download ef20071434_ex99-1slide12.jpg

GRAPHIC

Filename: ef20071434_ex99-1slide13.jpg · Sequence: 18

Binary file (154217 bytes)

Download ef20071434_ex99-1slide13.jpg

GRAPHIC

Filename: ef20071434_ex99-1slide14.jpg · Sequence: 19

Binary file (116500 bytes)

Download ef20071434_ex99-1slide14.jpg

GRAPHIC

Filename: ef20071434_ex99-1slide15.jpg · Sequence: 20

Binary file (168822 bytes)

Download ef20071434_ex99-1slide15.jpg

GRAPHIC

Filename: ef20071434_ex99-1slide16.jpg · Sequence: 21

Binary file (120570 bytes)

Download ef20071434_ex99-1slide16.jpg

GRAPHIC

Filename: ef20071434_ex99-1slide17.jpg · Sequence: 22

Binary file (105220 bytes)

Download ef20071434_ex99-1slide17.jpg

GRAPHIC

Filename: ef20071434_ex99-1slide18.jpg · Sequence: 23

Binary file (160345 bytes)

Download ef20071434_ex99-1slide18.jpg

GRAPHIC

Filename: ef20071434_ex99-1slide19.jpg · Sequence: 24

Binary file (134233 bytes)

Download ef20071434_ex99-1slide19.jpg

GRAPHIC

Filename: ef20071434_ex99-1slide20.jpg · Sequence: 25

Binary file (93995 bytes)

Download ef20071434_ex99-1slide20.jpg

GRAPHIC

Filename: ef20071434_ex99-1slide21.jpg · Sequence: 26

Binary file (318535 bytes)

Download ef20071434_ex99-1slide21.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 28

v3.26.1

Document and Entity Information

Apr. 24, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Apr. 24, 2026

Entity File Number

001-37568

Entity Registrant Name

PDS BIOTECHNOLOGY CORPORATION

Entity Central Index Key

0001472091

Entity Incorporation, State or Country Code

Entity Tax Identification Number

26-4231384

Entity Address, Address Line One

303A College Road East

Entity Address, City or Town

Princeton

Entity Address, State or Province

Entity Address, Postal Zip Code

08540

City Area Code

800

Local Phone Number

208-3343

Title of 12(b) Security

Common Stock, par value $0.00033 per share

Trading Symbol

PDSB

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration